Unless a thalamic tumor is diagnosed as a juvenile pilocytic astrocytoma (JPA), the outcome is expected to be poor. The duration of symptom resolution is somewhat dependent on the grade and growth pattern of the tumor. Bilateral growth that is defined on the MRI and a biopsy proven Grade III or IV tumor are poor prognostic indicators. (See Grading a Glioma.)
Other, more common, childhood cancers once thought to be incurable, such as leukemia, have seen remarkable improvements in survival rates over the past 30 to 40 years, as researchers unlocked their secrets and found effective treatments. But there has been very little research into pediatric brain tumors, because it’s so difficult to get funding for it.
Government grants and gifts from major foundations tend to support common cancers, where each advance benefits thousands of people. That makes sense, of course. But how can you tell a parent that not only is there no hope for their child, but that nobody is even working on it? The only way to improve the prognosis for thalamic gliomas and other rare and inoperable brain tumors in children is to study them, get to understand them better, and test innovative therapies for them.
That’s why we’ve launched the Thalamic Glioma Registry — it allows us to collect and study the data so desperately needed to advance the research and improve the odds. (Find out more about the Legacy Donation Program.)
Our Care Team
- Vice Chairman, Neurological Surgery
- Director, Pediatric Neurological Surgery
- Vice Chairman for Academic Affairs
- Professor of Neurological Surgery, Pediatric Neurosurgery
- Associate Residency Director
- Chief of Neurological Surgery, NewYork-Presbyterian Queens
- Co-director, Weill Cornell Medicine CSF Leak Program
Reviewed by Umberto Tosi, MD
Last reviewed/last updated: March 2022